PACB - Pacific Biosciences of California, Inc.
| Previous Close | 7.30 |
| Open | 7.30 |
| Bid | 7.34 x 1800 |
| Ask | 7.35 x 2900 |
| Day's Range | 7.34 - 7.38 |
| 52 Week Range | 2.02 - 7.84 |
| Volume | 518,901 |
| Avg. Volume | 1,702,225 |
| Market Cap | 1.108B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Apr 30, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.67 |
- Zacks•5 days ago
Pacific Biosciences (PACB) Up 3.8% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•20 days ago
Latest PacBio Sequencing Advancements Including Preview of Sequel II System to be Featured at Annual AGBT Conference
MENLO PARK, Calif., Feb. 26, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and.
- GuruFocus.com•28 days ago
Prem Watsa Buys 7 Stocks in 4th Quarter
Fairfax CEO keeps BlackBerry and Seaspan but sees losses
- Zacks•last month
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
- Zacks•last month
Pacific Biosciences of California (PACB) Reports Q4 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -61.54% and -7.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Pacific Biosciences: 4Q Earnings Snapshot
The Menlo Park, California-based company said it had a loss of 21 cents per share. The maker of genetic analysis technology posted revenue of $19.5 million in the period, which did not meet Street forecasts. ...
- GlobeNewswire•last month
Pacific Biosciences Announces Fourth Quarter and Annual 2018 Financial Results
MENLO PARK, Calif., Feb. 11, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31,.
- Motley Fool•last month
5 Things to Expect From Illumina in 2019
What's in store this year for the world's top gene-sequencing company?
- Zacks•2 months ago
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
LMNX or PACB: Which is a Better MedTech Investment Pick?
Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.
- GlobeNewswire•3 months ago
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Red Hat, LSC Communications, Intersections, and Pacific Biosciences on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 31, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Red Hat, Inc., LSC.
- ACCESSWIRE•3 months ago
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of Pacific Biosciences of California, Inc. Scheduled For A Shareholder Vote On January 24, 2019 – PACB
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / JuanMonteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
- GlobeNewswire•3 months ago
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Pacific Biosciences of California, Inc. (PACB) on Behalf of Stockholders and Encourages PACB Investors to Contact the Firm
NEW YORK, Dec. 10, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Pacific Biosciences of California, Inc. (NASDAQ:.
- Business Wire•3 months ago
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS: PACB) related to the Company’s entry into an agreement to be acquired by Illumina, Inc. (“Illumina”) (NASDAQ GS: ILMN) in a transaction announced on November 1, 2018 (the “Proposed Transaction”). On November 1, 2018, the Board caused Pacific Biosciences to enter into an agreement and plan of merger (the “Merger Agreement”) with Illumina. Pursuant to the terms of the agreement, shareholders of Pacific Biosciences will receive $8.00 in cash for each share of Pacific Biosciences common stock.
- PR Newswire•3 months ago
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Pacific Biosciences of California, Inc. - PACB
NEW YORK , Dec. 6, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- Zacks•3 months ago
Here's Why You Should Hold Pacific Biosciences (PACB) Now
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Market Realist•4 months agoPacific Biosciences of California Has Seen Solid Growth in 2018
Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.
- Zacks•4 months ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
- Zacks•4 months ago
Pacific Biosciences Offers Insights on Aedes aegypti Genome
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
- Motley Fool•4 months ago
Is This the Real Reason Illumina Acquired Pacific Biosciences?
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
- GlobeNewswire•4 months ago
PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito
Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.
- ACCESSWIRE•4 months ago
Pacific Biosciences Agrees to be Acquired in an All Cash Transaction, Analysts Review
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.
- Motley Fool•4 months ago
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
